Cargando…

Paclitaxel Resistance Modulated by the Interaction between TRPS1 and AF178030.2 in Triple-Negative Breast Cancer

Paclitaxel is a chemotherapeutic agent that acts as an inhibitor of cellular mitosis and has been widely used in the treatment of triple-negative breast cancer (TNBC). However, paclitaxel resistance is one of the major reasons that contribute to the high failure rates of chemotherapy and the relapse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Tao, Zhang, Tingrong, Zhang, Yao, Zhou, Bin, Lu, Xiangdong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986375/ https://www.ncbi.nlm.nih.gov/pubmed/35399640 http://dx.doi.org/10.1155/2022/6019975

Ejemplares similares

TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin
por: Almási, Szintia, et al.
Publicado: (2023)

TRPs in Pain Sensation
por: Jardín, Isaac, et al.
Publicado: (2017)

Trps1-deficient transplanted skin gave rise to a substantial amount of hair: Trps1 is unnecessary for hair development
por: Zhang, Yingzhe, et al.
Publicado: (2019)

TRPS1: A Marker of Follicular Differentiation
por: Rybski, Kristin J., et al.
Publicado: (2023)

Association of TRPS1 gene with different EMT markers in ERα-positive and ERα-negative breast cancer
por: Su, Peng, et al.
Publicado: (2014)

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
por: Qi, Yanfeng, et al.
Publicado: (2012)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

TRPS1 Suppresses Breast Cancer Epithelial-mesenchymal Transition Program as a Negative Regulator of SUZ12
por: Hu, Jing, et al.
Publicado: (2018)

Preparation and anti-triple-negative breast cancer cell effect of a nanoparticle for the codelivery of paclitaxel and gemcitabine
por: Yang, Fan, et al.
Publicado: (2023)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Connexin 43 Modulates the Cellular Resistance to Paclitaxel via Targeting β-Tubulin in Triple-Negative Breast Cancer
por: Fu, Yun, et al.
Publicado: (2020)

TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer
por: Witwicki, Robert M., et al.
Publicado: (2018)

Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer
por: Lian, Bi, et al.
Publicado: (2020)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

TRPS1 Confers Multidrug Resistance of Breast Cancer Cells by Regulating BCRP Expression
por: Hu, Jing, et al.
Publicado: (2020)

Trps1 is associated with the multidrug resistance of lung cancer cell by regulating MGMT gene expression
por: Liu, Hongxiang, et al.
Publicado: (2018)

TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells
por: Elster, Dana, et al.
Publicado: (2018)

Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer
por: Li, Yi, et al.
Publicado: (2019)

Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA
por: Zhang, Qian, et al.
Publicado: (2020)

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
por: Blanchard, Zannel, et al.
Publicado: (2015)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

TRPs in Ovarian Serous Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic Targets
por: Zhang, Cheng, et al.
Publicado: (2022)

Self-Assembly Engineering Nanodrugs Composed of Paclitaxel and Curcumin for the Combined Treatment of Triple Negative Breast Cancer
por: Zuo, Shuting, et al.
Publicado: (2021)

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

TRPS1 regulates estrogen-receptor binding and histone acetylation at enhancers
por: Serandour, A.A, et al.
Publicado: (2018)

Antagonistic Pharmacological Interaction between Sirtuin Inhibitor Cambinol and Paclitaxel in Triple-Negative Breast Cancer Cell Lines: An Isobolographic Analysis
por: Wawruszak, Anna, et al.
Publicado: (2022)

Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage
por: Reeder, A, et al.
Publicado: (2015)

Increased Expression of TRPS1 Affects Tumor Progression and Correlates with Patients' Prognosis of Colon Cancer
por: Hong, Jun, et al.
Publicado: (2013)

Gambogic acid increases the sensitivity to paclitaxel in drug-resistant triple-negative breast cancer via the SHH signaling pathway
por: Wang, Yonghui, et al.
Publicado: (2019)

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer
por: Liu, Xi-Yu, et al.
Publicado: (2020)

Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention
por: Wang, Hongkun, et al.
Publicado: (2020)

Molecular Imaging of Oxygenation Changes during Immunotherapy in Combination with Paclitaxel in Triple Negative Breast Cancer
por: Napier, Tiara S., et al.
Publicado: (2023)

Delineation of the Germline and Somatic Mutation Interaction Landscape in Triple-Negative and Non-Triple-Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

Investigating the Heterogeneity of Immune Cells in Triple-Negative Breast Cancer at the Single-Cell Level before and after Paclitaxel Chemotherapy
por: Zhao, Heng, et al.
Publicado: (2023)

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
por: Wang, Meng, et al.
Publicado: (2021)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye, Jun, et al.
Publicado: (2016)

A central role for TRPS1 in the control of cell cycle and cancer development
por: Wu, Lele, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vg6sltmmd21c0lf1ge7db22kfc